Quince Therapeutics’ novel method of delivering steroids in a patient’s own red blood cells has turned out to be a bust in ataxia-telangiectasia (A-T), a rare inherited disorder. | Quince Therapeutics ...
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled a total of 65 participants in the US, Europe and Australia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results